International Stroke Conference (ISC)

ANGEL-TNK demonstrated Tenecteplase's potential to enhance microcirculation post-thrombectomy, reducing brain tissue damage from inadequate blood flow.

The director of the Cerebrovascular Center at Mount Sinai discussed how results from the ESCAPE-MeVO trial highlight the impact of anesthesia rates, thrombectomy techniques, and the need for rigorous clinical trials to minimize bias. [WATCH TIME: 3 minutes]

The president of the American Heart Association discussed how precision medicine, advanced imaging, and expanded treatment windows are transforming stroke care, as displayed at ISC 2025. [WATCH TIME: 5 minutes]

The president of the American Heart Association provided post-conference commentary on the advances shaping stroke care and excitement behind this year’s International Stroke Conference. [WATCH TIME: 3 minutes]

The director of the Cerebrovascular Center at Mount Sinai highlighted key differences in patient selection criteria and trial designs that may influence how stroke treatment data is applied in clinical practice. [WATCH TIME: 5 minutes]

Andrei Alexandrov, MD, chair of the department of neurology at the University of Arizona College of Medicine, covered the latest advancements in stroke care from ISC 2025, from expanding thrombectomy indications to evolving imaging techniques.

Stroke neurologists Lauren Sansing, MD, MS, FAHA, FANA, and Bijoy Menon, MD, MSc, FRCPC, provided a post-conference perspective on the emerging data and research presented at the 2025 International Stroke Conference.

The director of the Cerebrovascular Center at Mount Sinai talked about findings from recent trials presented at ISC 2025 investigating thrombectomy for distal vessel occlusions. [WATCH TIME: 4 minutes]

The professor and chair of the neurology department at the University of Arizonia, Phoenix, gave clinical insights on the notable progress in the stroke treatment world, highlighted by advances presented at the 2025 International Stroke Conference. [WATCH TIME: 3 minutes]

The director of the neurological disease center at Beijing Anzhen Hospital talked about assessing the potential benefits and safety of intra-arterial tenecteplase in highly selected poststroke patients. [WATCH TIME: 6 minutes]

In addition to failing to separate itself on the primary end point, EVT + best medical care was associated with higher rates of serious adverse events (33.9% vs 25.7%) and mortality (13.3% vs 8.4%) compared to best medical care alone.

In a recently presented study at ISC 2025, poststroke patients reported no additional benefit from using transcranial direct current stimulation as a potential intervention for recovery.

The associate professor of neurology at McMaster University talked about findings from secondary analyses on the phase 4 ANNEXA-I trial assessing andexanet alfa in patients with acute intracerebral hemorrhage. [WATCH TIME: 10 minutes]

The professor of emergency medicine at Washington University in St. Louis and associate professor of neurosurgery at UTHealth Houston talked about results from the phase 3 MOST trial assessing argatroban and eptifibatide in acute ischemic stroke. [WATCH TIME: 3 minutes]

The professor of neurology at University of South Florida talked about the cost-effectiveness of insertable cardiac monitors to detect new atrial fibrillation in patients with large-artery or small-vessel disease stroke. [WATCH TIME: 4 minutes]

The associate professor of neurology at Brown University talked about findings from an observational study investigating treatment options antiplatelets and anticoagulation for cervical artery dissection. [WATCH TIME: 8 minutes]

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on the biggest learning experiences over the past decade for Cleveland Clinic’s mobile stroke unit. [WATCH TIME: 4 minutes]

The medical director of the Stroke Center at Weill Cornell Medicine talked about results from a recent study on the risk of stroke in patients on assisted reproductive technologies during delivery hospitalization. [WATCH TIME: 4 minutes]

The vascular neurologist and director of the residency program at Cleveland Clinic provided perspective on a recently conducted study showing the benefits of timely treatment through mobile stroke units for patients with acute intracerebral hemorrhage. [WATCH TIME: 6 minutes]

The medical director of the Cooper Neurological Institute and the professor of neurology at Yale University School of Medicine shared a few highlights from research presented at ISC 2024. [WATCH TIME: 7 minutes]

The professor of nursing and neurology at the University of Tennessee Health Science Center talked about findings from a study investigating head-of-bed position in patients undergoing thrombectomy which was presented at ISC 2024. [WATCH TIME: 6 minutes]

The professor of neurology and director of the Stanford Stroke Center provided commentary on clinical implications of findings from the TIMELESS trial assessing tenecteplase initiated in the late window after stroke onset. [WATCH TIME: 4 minutes]

The postdoctoral research fellow in neurology at Harvard Medical School talked about the potential of a portable low field MRI device to provide timely and cost-effective diagnoses for stroke. [WATCH TIME: 4 minutes]

Cynthia Tsai, MD, PhD, assistant professor of neurology at National Taiwan University College of Medicine, shared her clinical viewpoint on findings from a study presented at ISC 2024 using amyloid PET scans to differentiate between CAA and AD.

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo discussed the questions that still remain following the EMBOLISE trial and the use of embolization in the treatment of subacute and subdural hematoma. [WATCH TIME: 5 minutes]

In a recent study presented at ISC 2024, results revealed that patients who used assisted reproductive technologies therapy during hospitalization for delivery had a higher risk of stroke than those who did not use such therapies.

A recent study showed anticoagulation reduced ischemic stroke risk in patients with cervical artery dissection; however, cautioned is warned about the importance of transitioning to antiplatelet therapy at a certain point.

Topline results from the RESCUE trial indicate that RNS60, an anti-inflammatory agent, demonstrates safety and potential efficacy in acute ischemic stroke.